Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

74.99USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$74.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,223,586
52-wk High
$89.53
52-wk Low
$64.27

Select another date:

Mon, Sep 24 2018

Photo

Gilead to launch generic versions of its hepatitis drugs

Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Gilead to launch generic versions of its hepatitis drugs

Sept 24 Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Brazil court strips Gilead of hepatitis C drug patent

BRASILIA/SAO PAULO A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the behest of a presidential candidate who pushed for the move, paving the way for cheaper generics.

UPDATE 1-Brazil court strips Gilead of hepatitis C drug patent

BRASILIA/SAO PAULO, Sept 24 A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the behest of a presidential candidate who pushed for the move, paving the way for cheaper generics.

Brazil court strips Gilead hepatitis drug patent, politician says

BRASILIA/SAO PAULO, Sept 24 A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

UPDATE 1-Galapagos, Gilead bask in $4-6 bln new drug sales hope

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

UK rejects Gilead's CAR-T cancer cell therapy as too expensive

LONDON A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain's state-funded health service, the country's healthcare cost agency NICE said on Tuesday.

UK rejects Gilead's CAR-T cancer cell therapy as too expensive

LONDON, Aug 28 A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain's state-funded health service, the country's healthcare cost agency NICE said on Tuesday.

UPDATE 2-Long-acting injection a shot in the arm for GSK's HIV business

* GSK hopes to gain market share from market leader Gilead (Updates with latest GSK and Gilead share price moves)

Gilead CEO Milligan, Chairman Martin to step down

Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men.

Select another date: